Media coverage about Ardelyx (NASDAQ:ARDX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.8348558639305 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several analysts have issued reports on the stock. Cantor Fitzgerald set a $12.00 price target on shares of Ardelyx and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. BTIG Research decreased their price target on shares of Ardelyx from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, May 23rd. ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of Ardelyx from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $14.13.
Shares of Ardelyx (ARDX) opened at 5.35 on Wednesday. Ardelyx has a 52-week low of $4.05 and a 52-week high of $16.30. The firm has a 50-day moving average of $5.10 and a 200 day moving average of $8.31. The firm’s market capitalization is $253.83 million.
Ardelyx (NASDAQ:ARDX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.09. Analysts predict that Ardelyx will post ($2.19) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was published by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thestockobserver.com/2017/09/13/ardelyx-ardx-receives-media-sentiment-score-of-0-13.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.